MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41586-021-03673-2

Медицинская библиотека · Nature · 2021

Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.

Ku Zhiqiang, Xie Xuping, Hinton Paul R, Liu Xinli, Ye Xiaohua, Muruato Antonio E, Ng Dean C, Biswas Sujit, Zou Jing, Liu Yang, Pandya Deepal, Menachery Vineet D, Rahman Sachi, Cao Yu-An, Deng Hui, Xiong Wei, Carlin Kevin B, Liu Junquan, Su Hang, Haanes Elizabeth J, Keyt Bruce A, Zhang Ningyan, Carroll Stephen F, Shi Pei-Yong, An Zhiqiang

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Resistance represents a major challenge for antibody-based therapy for COVID-191-4. Here we engineered an immunoglobulin M (IgM) neutralizing antibody (IgM-14) to overcome the resistance encountered by immunoglobulin G (IgG)-based therapeutics. IgM-14 is over 230-fold more potent than its parental IgG-14 in neutralizing SARS-CoV-2. IgM-14 potently neutralizes the resistant virus raised by its corresponding IgG-14, three variants of concern-B.1.1.7 (Alpha, which first emerged in the UK), P.1 (Gamma, which first emerged in Brazil) and B.1.351 (Beta, which first emerged in South Africa)-and 21 other receptor-binding domain mutants, many of which are resistant to the IgG antibodies that have been authorized for emergency use. Although engineering IgG into IgM enhances antibody potency in general, selection of an optimal epitope is critical for identifying the most effective IgM that can overcome resistance. In mice, a single intranasal dose of IgM-14 at 0.044 mg per kg body weight confers prophylactic efficacy and a single dose at 0.4 mg per kg confers therapeutic efficacy against SARS-CoV-2. IgM-14, but not IgG-14, also confers potent therapeutic protection against the P.1 and B.1.351 variants. IgM-14 exhibits desirable pharmacokinetics and safety profiles when administered intranasally in rodents. Our results show that intranasal administration of an engineered IgM can improve efficacy, reduce resistance and simplify the prophylactic and therapeutic treatment of COVID-19.

Для цитирования: Ku Zhiqiang, Xie Xuping, Hinton Paul R, Liu Xinli, Ye Xiaohua, Muruato Antonio E, Ng Dean C, Biswas Sujit, Zou Jing, Liu Yang, Pandya Deepal, Menachery Vineet D, Rahman Sachi, Cao Yu-An, Deng Hui, Xiong Wei, Carlin Kevin B, Liu Junquan, Su Hang, Haanes Elizabeth J, Keyt Bruce A, Zhang Ningyan, Carroll Stephen F, Shi Pei-Yong, An Zhiqiang. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.. Nature. 2021. DOI: 10.1038/s41586-021-03673-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.